SARS-CoV-2 variants have emerged with enhanced pathogenicity and transmissibility, and escape from pre-existing immunity, suggesting first-generation vaccines and monoclonal antibodies may now be less effective. Here we present an approach for preventing clinical sequelae and the spread of SARS-CoV-2 variants.
Dr. Jim Wilson, the Director of the Gene Therapy Program at the University of Pennsylvania, will deliver a keynote address at the first Global CMT Research Convention in September 2021. CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, will host the convention in Alexandria, Virginia. CMTRF's CEO announced that several hundred Charcot-Marie-Tooth world leaders will gather to accelerate collaboration and advancements in research.
In collaboration with the Foundation for Angelman Syndrome Therapeutics (FAST), The Gene Therapy Program at the University of Pennsylvania is pleased to unveil a research plan for the development of a microRNA (miRNA) approach as a potential therapeutic for the treatment of Angelman syndrome.
The Gene Therapy Program at The University of Pennsylvania is expanding. The Discovery Labs has signed a foundational lease the Gene Therapy Program (GTP), which will use Discovery Labs’ suburban campus for a portion of its expanding research operations focused on the development of genetic medicines for rare and orphan diseases, as well as acquired and pandemic infectious diseases, such as COVID-19.
Dr. Jim Wilson, Director of the Gene Therapy Program at the University of Pennsylvania, was featured in Endpoints News' list of 60 biopharma pioneers over 60. The list highlights "a generation of living pioneers who have been breaking new paths in R&D for decades."
G2 Bio Companies is a partnership between the University of Pennsylvania's Gene Therapy Program, Dr. James Wilson, Dr. Tachi Yamada and Temasek. Temasek committed to invest $200 million to develop next-generation gene therapy companies with Penn’s Gene Therapy Program.
